HIV 진단약 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 모드별, 검사 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

HIV Diagnostics Market Size, Share & Trends Analysis Report By Product (Consumables, Instruments), By Mode (Self-test), By Test Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,257,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,645,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,420,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

HIV 진단약 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 HIV 진단 의약품 시장 규모는 2025-2030년 연평균 5.0%의 연평균 복합 성장률(CAGR)로 확대되며, 2030년에는 15억 5,000만 달러에 달할 것으로 예상됩니다.

이러한 시장 성장의 주요 요인으로는 자원이 한정된 환경에서 환자 치료 현장에서 쉽게 시행할 수 있는 보다 민감한 HIV 진단 POC 검사에 대한 개발 요구가 증가하고 있다는 점을 들 수 있습니다. 예측 기간 중 다수의 신규 신속 POC 검사가 도입될 것으로 예상되는 검사 기술의 개발은 HIV 진단 의약품 시장의 성장을 가속하는 주요 요인으로 작용할 것으로 예상됩니다. 또한 HIV에 대한 정부 프로그램 및 캠페인, 질병 이환율을 낮추기 위한 전 세계 의료 노력, 중동 및 동부 지역의 높은 미충족 수요의 존재는 향후 성장 기회에 유리하게 작용할 것으로 예상되는 몇 가지 주요 요인으로 꼽힙니다.

HIV 진단약 시장 : 분석 개요

• 항체 검사 분야는 2024년 56.6%의 가장 큰 매출 점유율을 차지하며 업계를 지배하고 있습니다. 이 큰 점유율은 ELISA, 홈 액세스 건조 혈액 반점, 웨스턴 블롯 검사 IFA, RIPA를 포함한 이러한 검사의 높은 시장 사용률과 보급률로 설명할 수 있습니다. 이러한 검사는 민감도가 높고 정확하므로 HIV-1 및 HIV-2의 선별 및 확인에 가장 일반적으로 사용됩니다.
• 바이러스 부하 검사와 CD4 검사도 2024년 시장에서 상당한 점유율을 차지하고 있습니다. 이러한 검사는 더 민감하고 빠르며 POC(Point of Care)로 휴대가 가능하므로 자원이 부족한 HIV 감염 지역에서 시장에서의 유용성과 접근성을 높일 수 있습니다.
• 예측 기간 중 현재 임상 개발 중이거나 주요 기업의 제품 파이프라인에 있는 많은 새로운 POC HIV 진단 제품이 상용화될 것으로 예상됩니다. 이러한 제품 증가는 예측 기간 중 이 시장의 성장을 가속할 것으로 예상됩니다.
• 아시아태평양의 HIV 진단 의약품 산업은 예측 기간 중 괄목할 만한 성장률을 보일 것으로 예상됩니다. 이 지역의 R&D 발전은 HIV 진단 의약품 시장의 중요한 촉진요인으로 작용하고 있습니다.
• 라틴아메리카의 HIV 진단제 시장은 예측 기간 중 상당한 성장을 보일 것으로 예상되며, 지난 10년간 라틴아메리카에서 28%, 카리브해에서 57% 감소한 HIV 관련 사망자 감소가 HIV 진단제 시장을 독점했습니다.

목차

제1장 분석 방법·범위

제2장 개요

제3장 HIV 진단약 시장 : 변동 요인·경향·범위

• 시장 연관 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• HIV 진단약 시장 : 분석 툴
  • 업계 분석 : Porter의 산업 분석
  • PESTEL 분석

제4장 HIV 진단약 시장 : 제품별 추정·동향 분석

• 시장 점유율 : 제품별(2024년·2030년)
• 부문 대시보드
• 세계의 HIV 진단약 시장 : 제품별 전망
• 시장 규모 예측과 동향 분석(2018-2030년)
  • 소모품
  • 기기
  • 소프트웨어와 서비스

제5장 HIV 진단약 시장 : 모드별 추정·동향 분석

• 시장 점유율 : 모드별(2024년·2030년)
• 부문 대시보드
• 세계의 HIV 진단약 시장 : 모드별 전망
• 시장 규모 예측과 동향 분석(2018-2030년)
  • 셀프 테스트
  • 실험실 기반

제6장 HIV 진단약 시장 : 검사 유형별 추정·동향 분석

• 시장 점유율 : 검사 유형별(2024년·2030년)
• 부문 대시보드
• 세계의 HIV 진단약 시장 : 검사 유형별 전망
• 시장 규모 예측과 동향 분석(2018-2030년)
  • 항체 검사
  • 바이러스 부하 검사
  • CD4 검사
  • 기타

제7장 HIV 진단약 시장 : 최종 용도별 추정·동향 분석

• 시장 점유율 : 최종 용도별(2024년·2030년)
• 부문 대시보드
• 세계의 HIV 진단약 시장 : 최종 용도별 전망
• 시장 규모 예측과 동향 분석(2018-2030년)
  • 진단 검사실
  • 병원·진료소
  • 재택 의료

제8장 HIV 진단약 시장 : 지역별 추정·동향 분석

• 시장 점유율 : 지역별(2024년·2030년)
• 부문 대시보드
• 세계의 HIV 진단약 시장 : 지역별 전망
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제9장 경쟁 구도

• 최근 동향과 영향 분석 : 주요 시장 참여 기업별
• 기업/경쟁의 분류
• 벤더 구도
  • 주요 기업의 시장 점유율(2024년)
  • Alere Inc.
  • Abbott
  • Bristol-Myers Squibb Company
  • Janssen Global Services, LLC
  • Gilead Sciences, Inc.
  • Merck &Co. Inc.
  • VIIV Healthcare
  • BD
  • Beckman Coulter, Inc.
  • Sysmex Europe SE
  • Apogee Flow Systems
  • Point Care
  • Zyomtronix, Inc.
  • Mylan NV
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare GmbH
  • QIAGEN

KSA

영문 목차

영문목차

HIV Diagnostics Market Growth & Trends:

The global HIV diagnostics market size is estimated to reach USD 1.55 billion by 2030, expanding at a CAGR of 5.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Key factors accounting for the growth of this market include the growing need in for the development of more sensitive HIV diagnostic point of care tests which can be easily implemented at the location of patient care in resource-limited settings. Technological development of tests which is expected to introduce a number of novel rapid, point-of-care tests throughout the forecast period is a primary factor expected to fuel the growth of the HIV diagnostics market. Furthermore, government programs and campaigns initiated against HIV, global healthcare efforts to reduce disease incidence, and the presence of high unmet demand in the Middle Eastern and Eastern regions of the market are some key factors expected to serve as lucrative future growth opportunities.

HIV Diagnostics Market Report Highlights:

• The antibody test segment dominated the industry and accounted for the largest revenue share of 56.6% in 2024. This large share can be accounted for by the high market usage and penetration rates of these tests which include, ELISA, home access dried blood spot, western blot testing IFA, and RIPA. These tests are highly sensitive and accurate and thus are most commonly used for screening and confirmation of HIV-1 & HIV-2.
• Viral Load testing and CD4 testing also accounted for a considerable share of the market in 2024. There is a prevalent in the market for the development of these tests which will make them more sensitive, rapid in nature, and portable to the point of care to enhance their market usability and accessibility in resource-limited HIV-affected regions.
• It is expected that during the forecast period, a number of novel point-of-care HIV diagnostic products will be commercialized which are currently under clinical development and in product pipelines of key market players. This increase in the range of products is expected to fuel the growth of this market over the forecast period.
• The Asia Pacific HIV diagnostics industry is expected to experience a notable growth rate during the forecast period. Advancements in research and development in the region are significant drivers for the HIV diagnostics market.
• The Latin America HIV diagnostics industry is expected to experience significant growth throughout the forecast period. The HIV diagnostics market is driven by the region's progress in reducing HIV-related deaths, which have declined by 28% in Latin America and 57% in the Caribbean over the past decade.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Mode
  • 1.2.3. Test Type
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Mode outlook
  • 2.2.3. Test type outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. HIV Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Advancements in Diagnostic Technologies
    • 3.2.1.2. Government Initiatives to Increase Accessibility
    • 3.2.1.3. Rising HIV Awareness and Screening Programs
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Advanced Diagnostics
    • 3.2.2.2. Stigma and Social Barriers
• 3.3. HIV Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. HIV Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global HIV Diagnostics Market by Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Consumables
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Instruments
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Software and Services
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. HIV Diagnostics Market: Mode Estimates & Trend Analysis

• 5.1. Mode Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global HIV Diagnostics Market by Mode Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Self-test
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Lab-based
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. HIV Diagnostics Market: Test Type Estimates & Trend Analysis

• 6.1. Test Type Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global HIV Diagnostics Market by Test Type Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Antibody Test
    • 6.4.1.1. HIV-1 Screening Tests
      • 6.4.1.1.1. ELISA/EIA
        • 6.4.1.1.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.1.2. Home Access Dried Blood Spot
        • 6.4.1.1.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 6.4.1.1.2.2. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.1.3. Rapid Tests (Dot plot, Agglutination Tests)
        • 6.4.1.1.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.1.2. HIV-1 Antibody Confirmatory Tests
      • 6.4.1.2.1. Western Blot Test
        • 6.4.1.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.2.2. Indirect Immunofluorescent Antibody Assay (IFA)
        • 6.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.2.3. Line Immunoassay
        • 6.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.2.4. RadioImmunoPrecipitation Assay (RIPA)
        • 6.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.1.3. HIV-2 & Group O Diagnostic Tests
      • 6.4.1.3.1. Blood Antibody Tests
        • 6.4.1.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.3.2. Dried Blood Spot (DBS) Test
        • 6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 6.4.1.3.3. Others and (Oral, Urine)
        • 6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.4.2. Viral load test
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.4.3. CD4 test
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.4.4. Others
    • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 7. HIV Diagnostics Market: End Use Estimates & Trend Analysis

• 7.1. End Use Market Share, 2024 & 2030
• 7.2. Segment Dashboard
• 7.3. Global HIV Diagnostics Market by End Use Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Diagnostic Laboratories
    • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 7.4.2. Hospitals & Clinics
    • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 7.4.3. Home Settings
    • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 8. HIV Diagnostics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Target disease prevalence
    • 8.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Target disease prevalence
    • 8.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Target disease prevalence
    • 8.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Target disease prevalence
    • 8.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Target disease prevalence
    • 8.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Target disease prevalence
    • 8.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Target disease prevalence
    • 8.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Target disease prevalence
    • 8.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Norway
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Target disease prevalence
    • 8.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/ reimbursement structure
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Target disease prevalence
    • 8.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Denmark
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/ reimbursement structure
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Target disease prevalence
    • 8.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Target disease prevalence
    • 8.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Target disease prevalence
    • 8.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. Target disease prevalence
    • 8.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Target disease prevalence
    • 8.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Target disease prevalence
    • 8.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ reimbursement structure
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Target disease prevalence
    • 8.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Target disease prevalence
    • 8.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.1.6. )
  • 8.8.2. Argentina
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Target disease prevalence
    • 8.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework/ reimbursement structure
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. Target disease prevalence
    • 8.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/ reimbursement structure
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Target disease prevalence
    • 8.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ reimbursement structure
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. Target disease prevalence
    • 8.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/ reimbursement structure
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Target disease prevalence
    • 8.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Key company market share analysis, 2024
  • 9.3.2. Alere Inc.
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Abbott
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Bristol-Myers Squibb Company
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Janssen Global Services, LLC
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Gilead Sciences, Inc.
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Merck & Co. Inc.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. VIIV Healthcare
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. BD
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Beckman Coulter, Inc.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Sysmex Europe SE
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Apogee Flow Systems
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Point Care
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. Zyomtronix, Inc.
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Product benchmarking
    • 9.3.14.4. Strategic initiatives
  • 9.3.15. Mylan N.V.
    • 9.3.15.1. Company overview
    • 9.3.15.2. Financial performance
    • 9.3.15.3. Product benchmarking
    • 9.3.15.4. Strategic initiatives
  • 9.3.16. F. Hoffmann-La Roche Ltd.
    • 9.3.16.1. Company overview
    • 9.3.16.2. Financial performance
    • 9.3.16.3. Product benchmarking
    • 9.3.16.4. Strategic initiatives
  • 9.3.17. Siemens Healthcare GmbH
    • 9.3.17.1. Company overview
    • 9.3.17.2. Financial performance
    • 9.3.17.3. Product benchmarking
    • 9.3.17.4. Strategic initiatives
  • 9.3.18. QIAGEN
    • 9.3.18.1. Company overview
    • 9.3.18.2. Financial performance
    • 9.3.18.3. Product benchmarking
    • 9.3.18.4. Strategic initiatives

관련자료